



US007250419B2

(12) **United States Patent**
Hardern et al.

(10) **Patent No.:** **US 7,250,419 B2**
(45) **Date of Patent:** ***Jul. 31, 2007**

(54) **TRISUBSTITUTED TRIAZOLOPYRIMIDINES
FOR USE IN PLATELET AGGREGATION
INHIBITION**

(75) Inventors: **David Hardern**, Sutton Bonington
(GB); **Anthony Ingall**, Loughborough
(GB); **Brian Springthorpe**,
Loughborough (GB); **Paul Willis**, West
Bridgford (GB); **Simon Guile**,
Loughborough (GB)

(73) Assignee: **AstraZeneca AB**, Sodertalje (SE)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **11/230,493**

(22) Filed: **Sep. 21, 2005**

(65) **Prior Publication Data**

US 2006/0025590 A1 Feb. 2, 2006

Related U.S. Application Data

(63) Continuation of application No. 10/323,655, filed on
Dec. 20, 2002, now Pat. No. 6,974,868, which is a
continuation of application No. 09/508,195, filed on
Mar. 8, 2000, now Pat. No. 6,525,060.

(51) **Int. Cl.**

A61K 31/519 (2006.01)

C07D 487/04 (2006.01)

A61P 7/02 (2006.01)

A61P 9/10 (2006.01)

(52) **U.S. Cl.** **514/261.1; 544/254**

(58) **Field of Classification Search** **544/254;**
514/261.6

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,620,676 A 4/1997 Jacobson et al.

6,251,910 B1 6/2001 Guile et al.

FOREIGN PATENT DOCUMENTS

WO 96/29345 9/1996

WO 97/19170 5/1997

OTHER PUBLICATIONS

Jin et al, "Molecular Basis for ADP-induced Platelet Activation,"
The Journal of Biological Chemistry, vol. 273, No. 4, pp. 2030-
2034(1998).

Puri et al, "Modulation of Platelet Responses by 2-[3-(Bromo-2-
oxopropylthio)]adenosine . . .," Archives of Biochemistry and
Biophysics, vol. 343, No. 1, pp. 140-145 (1997).

A. David Rodrigues; Commentary, "Use of in Vitro Human Metabo-
lism Studies in Drug Development; Biochemical Pharmacology",
vol. 48, No. 12, pp. 2147-2156, 1994.

Mistry, et al; "Glucuronidation In Vitro and In Vivo Comparison of
Intestinal and Hepatic Conjugation of Morphine, Naloxone, and
Buprenorphine; The American Society for Pharmacology and
Experimental Therapeutics"; vol. 15, No. 5; pp. 710-717; 1987.

J. Brian Houston; Commentary, "Utility of In Vitro Drug Metabo-
lism Data in Predicting In Vivo Metabolic Clearance; Biochemical
Pharmacology", vol. 47, No. 9, pp. 1469-1479, 1994.

Martindale Thirty-third edition; "The Complete Drug Reference";
Pharmaceutical Press; pp. 1086-1089.

Awni, et al; "The Effect of Mild or Moderate Hepatic Impairment
(Cirrhosis) on the Pharmacokinetics of Zileuton"; Clin.
Pharmacokinet, 29 (Suppl. 2): 49-61, 1995.

Primary Examiner—Mark L. Berch

Assistant Examiner—Susanna Moore

(74) *Attorney, Agent, or Firm*—Nixon & Vanderhye

(57) **ABSTRACT**

The invention provides new triazolo[4,5-d]pyrimidine com-
pounds, their use as medicaments, compositions containing
them and processes for their preparation.

14 Claims, No Drawings